论文部分内容阅读
2016年5月20日,国家卫生计生委、国家发改委等7部门联合发布了首批国家药品谈判结果,其中有慢性乙肝一线治疗药物替诺福韦酯、非小细胞肺癌靶向治疗药物埃克替尼和吉非替尼。经过国家药品价格谈判,这3种药品降价幅度分别为67%、54%和55%。根据中国统计年鉴最新数据显示,我国城市居民和农村居民主要疾病死亡率中,恶性肿瘤死亡率高居榜首。与此相对应,越来越多的靶向药物大量应
May 20, 2016, the National Health and Family Planning Commission, the National Development and Reform Commission and other departments jointly issued the first seven national drug negotiation results, including the first-line treatment of chronic hepatitis B tenofovir disoproxil, non-small cell lung cancer targeted drugs Ek Tenni and Gefitinib. After the national drug price negotiations, the price reduction of these three drugs were 67%, 54% and 55% respectively. According to the latest statistics from China Statistical Yearbook, among the mortality rates of major diseases of urban residents and rural residents in China, the death rate of malignant tumors topped the list. Correspondingly, more and more targeted drugs should be used in large quantities